Toll Free: 1-888-928-9744

TG Therapeutics, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

TG Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'TG Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the TG Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TG Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of TG Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of TG Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the TG Therapeutics, Inc.'s pipeline products

Reason to Buy

- Evaluate TG Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of TG Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the TG Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of TG Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of TG Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of TG Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 TG Therapeutics, Inc. Snapshot 5 TG Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 TG Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 TG Therapeutics, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 TG Therapeutics, Inc. - Pipeline Products Glance 13 TG Therapeutics, Inc. - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 TG Therapeutics, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 TG Therapeutics, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 TG Therapeutics, Inc. - Drug Profiles 17 ublituximab 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ibrutinib + ublituximab + TGR-1202 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 TG-1101 + TGR-1202 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 TGR-1202 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 IRAK4 Program 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibody to Agonize GITR for Hematological Malignacies and Solid Tumors 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 TG Therapeutics, Inc. - Pipeline Analysis 26 TG Therapeutics, Inc. - Pipeline Products by Target 26 TG Therapeutics, Inc. - Pipeline Products by Route of Administration 27 TG Therapeutics, Inc. - Pipeline Products by Molecule Type 28 TG Therapeutics, Inc. - Pipeline Products by Mechanism of Action 29 TG Therapeutics, Inc. - Recent Pipeline Updates 30 TG Therapeutics, Inc. - Discontinued Pipeline Products 39 Discontinued Pipeline Product Profiles 39 teriparatide acetate 39 TG Therapeutics, Inc. - Company Statement 40 TG Therapeutics, Inc. - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44
List of Tables
TG Therapeutics, Inc., Key Information 5 TG Therapeutics, Inc., Key Facts 5 TG Therapeutics, Inc. - Pipeline by Indication, 2015 7 TG Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8 TG Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9 TG Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015 10 TG Therapeutics, Inc. - Partnered Products in Pipeline, 2015 11 TG Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 12 TG Therapeutics, Inc. - Phase III, 2015 13 TG Therapeutics, Inc. - Phase II, 2015 14 TG Therapeutics, Inc. - Phase I, 2015 15 TG Therapeutics, Inc. - Preclinical, 2015 16 TG Therapeutics, Inc. - Pipeline by Target, 2015 26 TG Therapeutics, Inc. - Pipeline by Route of Administration, 2015 27 TG Therapeutics, Inc. - Pipeline by Molecule Type, 2015 28 TG Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 29 TG Therapeutics, Inc. - Recent Pipeline Updates, 2015 30 TG Therapeutics, Inc. - Discontinued Pipeline Products, 2015 39 TG Therapeutics, Inc., Subsidiaries 42



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify